|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 799 9th St NW |
Address2 | Suite 210 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Irving |
State | TX |
Zip Code | 75062 |
Country | USA |
|
5. Senate ID# 40021-00012
|
||||||||
|
6. House ID# 313240000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shoshana Krilow |
Date | 4/20/2022 12:43:00 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Build Back Better Act (H.R. 5376) - Supported inclusion of 4,000 Medicare-supported Graduate Medical Education slots as part of Build Back Better Act. Supported policies to encourage health care coverage and close the Medicaid coverage gap.
Medicare Sequestration - Urged Congress to continue delay of Medicare sequestration payment reductions and act to prevent sequestration cuts due to statutory PAYGO requirements.
Health Care Workforce - Supported legislation (S.834/H.R. 2256; S. 1438) to increase the number of Medicare-supported Graduate Medical Education (GME) slots. Supported the Opioid Workforce
Act (S. 1438/H.R. 3441).
Telehealth - Advocated for Congress to extend or make permanent flexibilities related to distant site and geographic limitations, expanding the provider types and services available to be reimbursed by Medicare. Supported provisions in the Consolidated Appropriations Act, 2022 (H.R. 2471) to temporarily extend certain flexibilities after the end of the public health emergency. Urged passage of the CONNECT for Health Act (S. 1512/H.R. 2903).
Social Determinants of Health and Health Equity - Engaged and offered feedback on proposals from CMS to provide resources and context to better assess patient obstacles to accessing health care and their impact on health care outcomes.
Supported passage of the Hospital Inpatient Services Modernization Act (S. 3792/H.R. 7053).
Supported passage of the Preserving Access to Home Infusion Act (H.R. 5067).
Advanced and Accelerated Payments Program - Urged Congress to act to provide further flexibility for repayment of advanced payments under the Medicare Advanced and Accelerated Payments Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Build Back Better Act (H.R. 5376) - Supported policies to encourage health care coverage and close the Medicaid coverage gap. Urged additional pandemic financial support for hospitals. Advocated for investments for hospitals and health care providers, including physical structure improvements, workforce and graduate medical education support.
Public Health Emergency - Advocated for HHS to further extend the declared Public Health Emergency.
Telehealth -Supported provisions in the Consolidated Appropriations Act, 2022 (H.R. 2471) to temporarily extend certain flexibilities after the end of the public health emergency. Supported passage of the CONNECT for Health Act (S. 1512/H.R. 2903) to make telehealth flexibilities permanent. Encouraged reimbursement parity for certain telehealth services and support for audio-only telehealth services.
Health Care Workforce - Urged passage of the Temporary Reciprocity to Ensure Access to Treatment (TREAT) Act (H.R. 708; S. 168); The Health Care Workforce Resilience Act (S. 1024/H.R. 2255); The Dr. Lorna Breen Health Care Provider Protection Act (S.610/H.R. 1667); The Resident Physician Shortage Reduction Act (S.834/H.R. 2256). The Opioid Workforce Act (S. 1438/H.R. 3441). Urged administration to examine practices of health care staffing agencies.
Health Care Supply Chain - Advocated for the importance of hospital group purchasing organizations, and highlighted role in supporting supply chain resiliency to secure essential, authentic medical supplies for hospitals throughout the course of the COVID-19 pandemic. Engaged to support policies to limit shortages of prescription drugs. Advocated for greater transparency in the health care supply chain for drugs and medical devices.
Prepare for and Respond to Existing Viruses, Emerging New Threats, and (PREVENT) Pandemics Act (S. 3799) - monitored introduction of PREVENT Pandemics Act. Supported inclusion of provisions to improve supply chain transparency and extend shelf life of prescription drugs.
Supported passage of the Integrity, Notification, Fairness in Online Retail Marketplaces (INFORM) Consumers Act (S. 963/H.R. 5502).
Provider Relief Fund - Urged HHS and Congress to offer greater flexibility and extend deadlines for hospitals to utilize PRF funding and provide clear guidance on reporting expectations. Supported Provider Relief Deadline Extension Act (S. 2493) and Provider Relief Fund Improvement Act (H.R. 5963/S.3611).
Drug Pricing - Reviewed options to further support modifications to the unapproved drugs initiative that would prevent or limit price increases for older, unapproved drugs. Supported changes to the 340B program and urged HHS to enforce guidance that would allow 340B Covered Entities to utilize contract pharmacies. Advocated for HHS to offer additional 340B Drug Pricing Program eligibility flexibility for hospitals that have had patient mix changed during the COVID-19 public health emergency (S. 773). Supported inclusion of provisions in Consolidated Appropriations Act, 2022 (H.R. 2471) that would extend eligibility for covered entities that may have lost eligibility during the public health emergency.
Medical Device User Fee Amendments - Urged greater authorities for the FDA to promote supply chain transparency.
Generic Drug User Fee Amendments - Supported rapid adoption of generic drug user fee amendments, and urged inclusion of clarifying language related to the Unapproved Drugs Initiative and the PASTUER Act (S.2076).
Social Determinants of Health and Health Equity - Shared insights and offered suggestions to CMS regarding health equity measurement, indices and data collection. Supported the Social Determinants Accelerator Act (H.R. 2503; S. 3039); The LINC to Address Social Needs Act (S. 509).
Antimicrobial resistance (S. 2076) - Supported passage of the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act.
Supported passage of Opioid Treatment Access Act (S. 3629/H.R. 6279).
Supported passage of Drug Shortage Shelf Life Extension Act (S. 3493).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Federal Emergency Management Agency (FEMA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Jenna |
Stern |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |